A clinical-stage biopharmaceutical company developing novel immunotherapies.
About
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies. Their proprietary TRACTr, TRACIr, and ARM platforms are designed to selectively modulate T cells to fight cancer and autoimmune diseases, aiming to transform patients' lives. They are currently evaluating their lead tumor-activated T cell engager (TRACTr) in a clinical trial for prostate cancer.
Tags
Total Employees
110
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
67Traction
59Team
30Visibility
22Profile
50Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Janux Therapeutics do?
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies. Their proprietary TRACTr, TRACIr, and ARM platforms are designed to selectively modulate T cells to fight cancer and autoimmune diseases, aiming to transform patients' lives. They are currently evaluating their lead tumor-activated T cell engager (TRACTr) in a clinical trial for prostate cancer.
How much funding has Janux Therapeutics raised?
Janux Therapeutics has raised a total of $181M in funding. The most recent round on record is Series B.
Where is Janux Therapeutics headquartered?
Janux Therapeutics is headquartered in San Diego, California, USA.
When was Janux Therapeutics founded?
Janux Therapeutics was founded in 2017.
What industry does Janux Therapeutics operate in?
Janux Therapeutics operates in Biotechnology, Pharmaceuticals, Healthcare, Immunotherapy, Biotech, HealthTech.
How many employees does Janux Therapeutics have?
Janux Therapeutics has approximately 110 people on record.
What is Janux Therapeutics's current status?
Janux Therapeutics's current operating status is: Public.
Similar Startups